Bionano to Accelerate Data Processing Solution for Optical Genome Mapping Workflow with NVIDIA

Bionano Genomics, announced a collaboration with NVIDIA to develop an acceleration platform for use in Bionano’s optical genome mapping (OGM) workflow. This collaboration is expected to significantly improve data processing speed while reducing time and cost associated with secondary analysis of OGM data. The computation platform is designed to enable a small laboratory and information technology footprint, which would allow for rapid decentralized deployment.

Artificial Intelligence News : Merlin AI, the Evolution of ChatGPT is Now a Freestanding Mobile App

By combining NVIDIA’s expertise in accelerated computing and the capabilities of the NVIDIA RTX 6000 Ada Generation professional GPU with Bionano’s knowledge in extraction, enzymatic treatment, and analysis of ultra-high molecular weight (UHMW) DNA molecules, the collaboration aims to develop on-premise and cloud-based solutions to keep pace with the anticipated data generation needs of high-throughput OGM workflows. The collaborative solution is projected to support analysis of 96 cancer workflows or just over 300 constitutional whole genomes per week and be integrated with Bionano’s NxClinical software for variant interpretation and reporting.

Bionano will preview the solution with NVIDIA at the Advances in Genome Biology and Technology (AGBT) General Meeting, which will take place February 6-9, 2023, in Hollywood, Florida.

“Bionano is focused on continuous upscaling of our end-to-end genome mapping solutions, and we see this collaboration with NVIDIA as an important part of that effort,” said Erik Holmlin, PhD, president and chief executive officer of Bionano Genomics. “We believe the solution we’re developing with NVIDIA will accelerate OGM analysis and enable future expansion into areas including CAR T-cell therapy research and bioprocessing.”

Artificial Intelligence Technology : How Artificial Intelligence Will Help Facilitate the Hybrid Working Environment

“Bionano’s optical genome mapping platform provides tremendous capability for genome-wide structural variant detection, which can have huge impact for cancer research and other areas of human health,” said George Vacek, global head of genomics alliances at NVIDIA. “By accelerating Bionano’s analysis, we will help achieve higher throughput in a smaller footprint at lower cost, enabling the application of this technology to new areas, both at scale and in smaller labs.”

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.

 AI in Advertising : AI in Advertising and Marketing – Hype, Disillusionment, Back to Hype Again?

 [To share your insights with us, please write to sghosh@martechseries.com]